Maria Ricci, Maria Silvia De Feo, Giorgia Maria Granese, Viviana Frantellizzi, Bruno Carabellese, Ennio Lubrano, Andrea Cimini
{"title":"18F-FDG PET/CT技术评估棕色脂肪组织:最新综述","authors":"Maria Ricci, Maria Silvia De Feo, Giorgia Maria Granese, Viviana Frantellizzi, Bruno Carabellese, Ennio Lubrano, Andrea Cimini","doi":"10.1080/17434440.2023.2283618","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This review provides an update of 18 F-fluorodeoxyglucose ([<sup>18</sup>F] FDG) for Brown adipose tissue (BAT) activity quantification, whose role is not completely understood.</p><p><strong>Areas covered: </strong>We conducted an unstructured search of the literature for any studies employing the [<sup>18</sup>F] FDG PET in BAT assessment. We explored BAT quantification both in healthy individuals and in different pathologies, after cold exposure and as a metabolic biomarker. The assessment of possible BAT modulators by using [<sup>18</sup>F] FDG PET is shown. Further PET tracers and novel developments for BAT assessments are also described.</p><p><strong>Expert opinion: </strong>Further PET tracers and imaging modalities are under investigation, but the [<sup>18F</sup>] FDG PET is currently the method of choice for the evaluation of BAT and further multicentric trials are needed for a better understanding of the BAT physiopathology, also after cold stimuli. The modulation of BAT activity, assessed by [<sup>18</sup>F] FDG PET imaging, seems a promising tool for the management of conditions such as obesity and type 2 diabetes. Moreover, an interesting possible correlation of BAT activation with prognostic [<sup>18</sup>F] FDG PET indices in cancer patients should be assessed with further multicentric trials.</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<sup>18</sup>F-FDG PET/CT technology for the assessment of brown adipose tissue: an updated review.\",\"authors\":\"Maria Ricci, Maria Silvia De Feo, Giorgia Maria Granese, Viviana Frantellizzi, Bruno Carabellese, Ennio Lubrano, Andrea Cimini\",\"doi\":\"10.1080/17434440.2023.2283618\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This review provides an update of 18 F-fluorodeoxyglucose ([<sup>18</sup>F] FDG) for Brown adipose tissue (BAT) activity quantification, whose role is not completely understood.</p><p><strong>Areas covered: </strong>We conducted an unstructured search of the literature for any studies employing the [<sup>18</sup>F] FDG PET in BAT assessment. We explored BAT quantification both in healthy individuals and in different pathologies, after cold exposure and as a metabolic biomarker. The assessment of possible BAT modulators by using [<sup>18</sup>F] FDG PET is shown. Further PET tracers and novel developments for BAT assessments are also described.</p><p><strong>Expert opinion: </strong>Further PET tracers and imaging modalities are under investigation, but the [<sup>18F</sup>] FDG PET is currently the method of choice for the evaluation of BAT and further multicentric trials are needed for a better understanding of the BAT physiopathology, also after cold stimuli. The modulation of BAT activity, assessed by [<sup>18</sup>F] FDG PET imaging, seems a promising tool for the management of conditions such as obesity and type 2 diabetes. Moreover, an interesting possible correlation of BAT activation with prognostic [<sup>18</sup>F] FDG PET indices in cancer patients should be assessed with further multicentric trials.</p>\",\"PeriodicalId\":94006,\"journal\":{\"name\":\"Expert review of medical devices\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert review of medical devices\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17434440.2023.2283618\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of medical devices","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17434440.2023.2283618","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
18F-FDG PET/CT technology for the assessment of brown adipose tissue: an updated review.
Introduction: This review provides an update of 18 F-fluorodeoxyglucose ([18F] FDG) for Brown adipose tissue (BAT) activity quantification, whose role is not completely understood.
Areas covered: We conducted an unstructured search of the literature for any studies employing the [18F] FDG PET in BAT assessment. We explored BAT quantification both in healthy individuals and in different pathologies, after cold exposure and as a metabolic biomarker. The assessment of possible BAT modulators by using [18F] FDG PET is shown. Further PET tracers and novel developments for BAT assessments are also described.
Expert opinion: Further PET tracers and imaging modalities are under investigation, but the [18F] FDG PET is currently the method of choice for the evaluation of BAT and further multicentric trials are needed for a better understanding of the BAT physiopathology, also after cold stimuli. The modulation of BAT activity, assessed by [18F] FDG PET imaging, seems a promising tool for the management of conditions such as obesity and type 2 diabetes. Moreover, an interesting possible correlation of BAT activation with prognostic [18F] FDG PET indices in cancer patients should be assessed with further multicentric trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
